Apparatus and Method for Ocular Treatment

• US 20080058704A1
• Filed: 04/29/2005
• Published: 03/06/2008
• Est. Priority Date: 04/29/2004
• Status: Abandoned Application

• Current Assignee: iScience Interventional Corporation
• Original Assignee: iScience Interventional Corporation
• Inventors: Conston, Stanley, Kupiecki, David, Nash, Michael, McKenzie, John, Yamamoto, Ronald, Hee, Michael
• Application Number:
  US11/587,784
• Publication Number:
  US 20080058704A1
• Time in Patent Office: Days
• US Class Current: 604/21
• CPC Class Codes: A61B 2090/3614 using optical fibre
• CPC Class Codes: A61B 90/39 Markers, e.g. radio-opaque or breast lesions markers
• CPC Class Codes: A61F 2009/00863 Retina
• CPC Class Codes: A61F 2009/00865 Sclera
• CPC Class Codes: A61F 2009/00872 Cornea
• CPC Class Codes: A61F 2009/00887 Cataract
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00736 Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments A61F9/008 takes precedence
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61F 9/008 using laser
• CPC Class Codes: A61F 9/009 Auxiliary devices making contact with the eyeball and coupling in laser light, e.g. goniolenses apparatus for eye examination A61B3/0008

Abstract

The invention provides tools, materials and related methods to surgically access the suprachoroidal space of an eye for the purpose of performing minimally invasive surgery or to deliver drugs to the eye. The invention provides a flexible microcannula device (11, 13) that may be placed into the suprachoroidal space (12, 14) through a small incision (12A) of the overlying tissues, maneuvered into the appropriate region of the space, and then activated to treat tissues adjacent to the distal tip of the device.

Claims

1. A composite microcannula device with proximal and distal ends for access and advancement within the suprachoroidal space of the eye comprising,

a flexible tubular sheath having an outer diameter of up to about 1000 microns and configured to fit within the suprachoroidal space of the eye;

a proximal assembly configured for introduction and removal of materials and tools through said proximal end;

and a signal-producing beacon at said distal end to locate said distal end within the eye, wherein said signal-producing beacon is detectable visually or by non-invasive imaging.

2. A device according to claim 1 wherein said signal-producing beacon is detectable in the suprachoroidal space, the interposing scleral tissue external to the suprachoroidal space, and the interposing choroidal tissue internal to the suprachoroidal space.

3. A device according to claim 2, wherein said signal-producing beacon is configured to emit visible light at an intensity that is visible externally through said interposing tissues.

4. A device according to claim 1, wherein said signal-producing beacon comprises markers identifiable by non-invasive imaging.

5. A device according to claim 4, wherein said non-invasive medical imaging comprises ultrasound imaging, optical coherence tomography or opthalmoscopy.

6. A device according to claim 4 wherein said markers comprise an optical contrast marker.

7. A device according to claim 1 wherein said tubular sheath is curved in the range of 12 to 15 mm radius.

8. A device according to claim 1 wherein said tubular sheath accommodates at least one additional signal-producing beacon detectable visually or by non-invasive imaging to aid in judging placement and location.

9. A device according to claim 1 wherein said tubular sheath comprises polyamide, polyimide, polyether block amide, polyethylene terephthalate, polypropylene, polyethylene or fluoropolymer.

10. A device according to claim 1 wherein said tubular sheath comprises a lubricious outer coating.

11. A device according to claim 1 wherein said tubular sheath comprises an atraumatic distal tip.

12. A device according to claim 1 having a minimum length in the range of about 20 to about 30 mm to reach the posterior region of the eye from an anterior dissection into the suprachoroidal space.

13. A device according to claim 1 further comprising an implant deliverable at said distal end.

14. A device according to claim 13 wherein said implant comprises a space-maintaining material.

15. A device according to claim 13 wherein said implant comprises a drug.

16. A device according to claim 1 further comprising a sustained release drug formulation deliverable at said distal end.

17. A device according to claim 16 wherein said drug formulation comprises microparticles.

18. A device according to claim 17 wherein said microparticles are suspended in a hyaluronic acid solution.

19. A device according to claim 1 additionally comprising an inner member with a proximal end and a distal end, wherein said sheath and inner member are sized such that said inner member fits slidably within said sheath and said distal end of said inner member is adapted to provide tissue treatment to the eye through one or more openings in said distal end of said device.

20. A device according to claim 19 wherein said distal end of said inner member is adapted for tissue dissection, cutting, ablation or removal.

21. A device according to claim 19 wherein said inner member is curved in the range of 12 to 15 mm radius.

22. A device according to claim 19 wherein said inner member comprises a multi-lumen tube.

23. A device according to claim 19 wherein said inner member comprises steel, nickel titanium alloy or tungsten.

24. A device according to claim 19 wherein said inner member comprises an optical fiber.

25. A device according to claim 1 or 19 wherein said beacon provides illumination from the distal end of said device at an angle of about 45 to about 135 degrees from the axis of said device to be coincident with the area of intended tissue treatment.

26. A device according to claim 1 further comprising an optical fiber for imaging tissues within or adjacent to the suprachoroidal space.

27. A device according to claim 1 further comprising an energy-emitting source for treating blood vessels within or adjacent to the suprachoroidal space.

28. A device according to claim 27 wherein said source is capable of emitting laser light, thermal energy, ultrasound, or electrical energy.

29. A device according to claim 27 or 28 wherein said source is aligned with the location of said beacon to facilitate tissue targeting.

30. A composite microcannula device for implantation in the suprachoroidal space of an eye for delivery of fluids to the posterior region of the eye comprising,

a flexible tubular sheath having proximal and distal ends with an outer diameter of up to about 1000 microns configured to fit within the suprachoroidal space of the eye;

a self-sealing proximal fitting capable of receiving injections of fluids into said device,

wherein said distal end of said sheath is adapted for release of fluids from said device into the eye.

31. A device according to claim 30 further comprising a signal-producing beacon to locate said distal end within the suprachoroidal space during implantation wherein said signal-producing beacon is detectable visually or by non-invasive imaging.

32. A device according to claim 30 that is adapted for slow release of fluids from said distal end.

33. A device according to any of claims 30 to 32 wherein said fluids comprise drugs.

34. A method for treating the suprachoroidal space of an eye comprising

a) inserting a flexible tubular sheath having proximal and distal ends and an outer diameter of up to about of 1000 microns and an atraumatic distal tip into the suprachoroidal space;

b) advancing said sheath to the anterior region of the suprachoroidal space; and

c) delivering energy or material from said distal end to form a space for aqueous humor drainage.

35. The method according to claim 34 wherein said energy comprises mechanical, thermal, laser, or electrical energy sufficient to treat or remove scleral tissue in the vicinity of said distal end.

36. The method according to claim 34 wherein said material comprises a space-maintaining material.

37. A method for treating the posterior region of an eye comprising

a) inserting a flexible tubular sheath having proximal and distal ends and an outer diameter of up to about 1000 micron into the suprachoroidal space;

b) advancing said sheath to the posterior region of the suprachoroidal space; and

c) delivering energy or material from said distal end sufficient to treat the macula, retina, optic nerve or choroid.

38. The method according to claim 37 wherein said energy comprises mechanical, thermal, laser, or electrical energy sufficient to treat tissues in the vicinity of said distal end.

39. The method according to claim 37 wherein said material comprises a drug.

40. The method according to claim 39 wherein said material further comprises hyaluronic acid.

41. The method according to claim 39 wherein said drug comprises a neuroprotecting agent.

42. The method according to claim 39 wherein said drug comprises an anti-angiogenesis agent.

43. The method according to claim 39 wherein said drug comprises an anti-inflammatory agent.

44. The method according to claim 43 wherein said anti-inflammatory agent comprises a steroid.

45. A method for treating the tissues within or adjacent to the suprachoroidal space of an eye comprising

a) inserting a composite flexible microcannula device having proximal and distal ends and an outer diameter of up to about 1000 microns into the suprachoroidal space, said device comprising an atraumatic distal tip and an optical fiber to provide detection of tissues in the vicinity of said distal tip;

b) advancing said device to the posterior region of the suprachoroidal space;

c) detecting and characterizing tissues in the suprachoroidal space to identify target tissues; and

d) delivering energy from said distal end to treat said target tissues.

46. The method according to claim 45 wherein said energy comprises laser light, thermal, ultrasound or electrical energy.

47. The method according to claim 45 wherein said target tissues comprise blood vessels.